NCT02428270 2022-11-01
A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer
University Health Network, Toronto
Phase 2 Completed
Clinical Trials
4 trialsNCT01938443 2019-07-12
A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00996671 2017-06-14
FTIH
GlaxoSmithKline
Phase 1 Completed
NCT01138033 2017-05-11
Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed